October 29 - 31, 2009
Gaylord National Hotel and Convention Center
National Harbor, MD - Washington, D.C.
A record setting number of attendees converged in Washington, D.C. for the very successful iSBTc 24th Annual Meeting October 29-31, 2009 at the Gaylord National Hotel. Over 500 scientists, clinicians, students, fellows, researchers, and industry and regulatory representatives from 27 countries attended, shared cutting-edge science, and jointly celebrated the advancement and success of the immunotherapy/biological therapy field. There was much excitement among attendees centered on the high quality science, networking opportunities, and caliber of speakers and attendees present at the iSBTc 24th Annual Meeting.
The iSBTc 24th Annual Meeting set several records including:
Topics Presented / Discussed
Adopt ive Transfer | Monoclonal Antibodies / Combinations | |
Clinical | Trials of New AgentsRegulatory & Activated T Cell Subsets | |
Cytokines / Immunotherapy | Stem Cells / Circulating Tumor Cells | |
Enhancing Cancer Vaccines / Combinations | Targeted Therapeutics & Biological Therapy | |
Human Immunology | Viral & Cellular Proteomic Targets | |
Manipulation of the Tumor Microenvironment |
Lieping Chen, MD, PhD Johns Hopkins University School of Medicince |
Giorgio Trinchieri, MD National Cancer Institute |
Robert Ferris, MD, PhD University of Pittsburgh Cancer Institute |
Laurence Zitvogel, MD, PhD Institute Gustave Roussy |
Carl H. June, MD University of Pennsylvania |